NCT06960642 Dosage of Early Rehabilitation of ICU Patients
| NCT ID | NCT06960642 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Vienna |
| Condition | Critical Care, Intensive Care |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,000 participants |
| Start Date | 2025-12-14 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,000 participants in total. It began in 2025-12-14 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Rehabilitation already begins in the intensive care unit (ICU) to maintain or restore the functional capacity of ICU patients and to counteract the long-term effects of intensive care treatment. Mobilisation is an important component. The aim of this multinational observational study is to record and evaluate the different mobilisation practices for ICU patients worldwide. The investigators want to find out which forms of mobilisation in intensive care patients achieve the best results in terms of physical function, functional status and quality of life. The goal is to recruit over 6,000 patients internationally. No interventions will be carried out, only routine clinical data will be documented and standardised and already established physical tests and questionnaires will be used.
Eligibility Criteria
Inclusion Criteria: * Adults (≥ 18 years old) within 48 hours of ICU admission * Expected to stay \> 24 hours in the ICU Exclusion Criteria: * Patients who receive end-of-life care at the time of screening * Patients whose treatment plans are still under discussion and/or not all team members are committed to full active treatment * Patients whose functional status is unlikely to be obtainable * Patients with language barriers
Contact & Investigator
Stefan J Schaller, MD
PRINCIPAL INVESTIGATOR
Medical University of Vienna
Frequently Asked Questions
Who can join the NCT06960642 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Critical Care, Intensive Care. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06960642 currently recruiting?
Yes, NCT06960642 is actively recruiting participants. Contact the research team at erupt@muv.ac.at for enrollment information.
Where is the NCT06960642 trial being conducted?
This trial is being conducted at Vienna, Austria.
Who is sponsoring the NCT06960642 clinical trial?
NCT06960642 is sponsored by Medical University of Vienna. The principal investigator is Stefan J Schaller, MD at Medical University of Vienna. The trial plans to enroll 6,000 participants.